Source: European Medicines Agency (EU) Revision Year: 2019 Publisher: Ferrer Internacional, S.A., Gran Vía Carlos III, 94, 08028- Barcelona, España
ADASUVE 9.1 mg inhalation powder, pre-dispensed.
| Pharmaceutical Form |
|---|
|
Inhalation powder, pre-dispensed (inhalation powder). White device with a mouthpiece on one end and a pull-tab protruding from the other end. |
Each single-dose inhaler contains 10 mg loxapine and delivers 9.1 mg loxapine.
| Active Ingredient | Description | |
|---|---|---|
| Loxapine |
Loxapine binds with noradrenergic, histaminergic, and cholinergic receptors, and its interaction with these systems may influence the spectrum of its pharmacological effects. Loxapine is indicated for the rapid control of mild-to-moderate agitation in adult patients with schizophrenia or bipolar disorder. |
| List of Excipients |
|---|
|
None. |
The white inhaler (housing) is molded from a medical-grade polycarbonate.
Each inhaler is provided in a sealed, multilaminate aluminum foil pouch. ADASUVE 9.1 mg is supplied in a carton of 1 or 5 units.
Not all pack-sized may be marketed.
Ferrer Internacional, S.A., Gran Vía Carlos III, 94, 08028- Barcelona, España
EU/1/13/823/002 (5 single-dose inhalers)
EU/1/13/823/004 (1 single-dose inhaler)
Date of first authorisation: 20 February 2013
| Drug | Countries | |
|---|---|---|
| ADASUVE | Austria, Estonia, Spain, Hong Kong, Croatia, Ireland, Lithuania, Poland, Romania, Turkey, United Kingdom, United States |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
